Navigation Links
Next Generation Trevo® System Launched in Europe - Trevo® Pro
Date:9/6/2011

MOUNTAIN VIEW, Calif., Sept. 6, 2011 /PRNewswire/ -- Concentric Medical, Inc. today announced the full European launch of Trevo® Pro 4 System. This next standard in Stentriever™ technology has an enhanced design to further promote clot integration across clot types in patients suffering an acute ischemic stroke.

The Trevo® Pro 4 system is the next generation of Trevo Stentrievers from Concentric Medical and is used to remove thrombus in stroke patients. It has a unique wide-cell geometry allowing the clot to more easily incorporate in the device. This unique cell and strut architecture, coupled with its proven radial force profile, are designed to further enhance clot retrieval in all clot types with fewer passes of the device in the procedure.

The Trevo Pro 4 device was introduced to a limited number of leading stroke centers in the spring. Fifty cases were completed in an initial evaluation post CE mark with very positive feedback from clinicians in Europe.

"The Trevo® Pro 4 System is a significant advance in the field of mechanical thrombectomy. I have had the opportunity to utilize this device in many procedures and have found the clot integration astonishing, regardless of the complexity of the clot. On many occasions I have achieved revascularization with one pass of the device," said Professor Olav Jansen, Head of Neuroradiology at Universitatsklinikum Schleswig-Holstein, Kiel, Germany.

Maria Sainz, President and CEO of Concentric Medical, also commented: "The Trevo Pro System has improved the predictability of the interventional stroke procedure for physicians. The device redefines the standard for success for physicians and patients. Concentric Medical is very proud to be able to offer the latest advancement in Trevo technology along with a full array of complementary tools for the entire stroke interventional procedure."

About Concentric Medical

Concentric Medical is located in Mountain View, California and is a global leader in the development of endovascular devices for revascularizing stroke patients. Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies.

For more information about Concentric Medical, please visit www.concentric-medical.com.

About the Trevo System

The Trevo System is an innovative, high-performing, easy-to-use thrombus retrieval system. The main component of the Trevo System is the Trevo Retriever which introduces Stentriever™ technology, creating a new generation of retrieval devices to remove clots in acute stroke patients.  Concentric Medical is the pioneer in developing devices for ischemic stroke intervention. Since 2002, Concentric Medical's devices have been used in thousands of stroke patients worldwide. This experience has been incorporated into the design of the Trevo System to make thrombus removal an easier, faster and more predictable procedure.   The new Trevo System combined with the Merci®Retriever, DAC® (Distal Access Catheters) and Balloon Guide Catheter portfolio of products, further strengthens Concentric Medical's position as a global leader in acute ischemic stroke intervention.  

About Acute Ischemic Stroke

Stroke is one of the leading causes of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain.

Media Contact:
+1 650-938-2100
strokeinfo@concentric-medical.com


'/>"/>
SOURCE Concentric Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
3. Beaumont Patients 1st to get Next Generation of Radiation Treatment
4. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
5. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
6. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):